Kyverna Therapeutics, Inc. Common Stock (KYTX) is a publicly traded Healthcare sector company. As of November 9, 2026, KYTX trades at $5.11 with a market cap of $301.80M and a P/E ratio of -1.71. KYTX moved +4.61% today. Year to date, KYTX is -44.36%; over the trailing twelve months it is -31.17%. Its 52-week range spans $1.78 to $13.67. Analyst consensus is strong buy with an average price target of $30.33. Rallies surfaces KYTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kyverna’s miv-cel meets all primary and secondary endpoints in stiff person syndrome trial: Kyverna Therapeutics announced publication of registrational KYSA-8 trial results for miv-cel, which met all primary and secondary endpoints. A single dose improved mobility and disability, and all patients discontinued chronic immunotherapies.
| Metric | Value |
|---|---|
| Price | $5.11 |
| Market Cap | $301.80M |
| P/E Ratio | -1.71 |
| EPS | $-3.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.67 |
| 52-Week Low | $1.78 |
| Volume | 428.83K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-161.31M |
| Gross Margin | 0.00% |
4 analysts cover KYTX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.33.